Monitor for actual sale execution on Form 4 filings. The proposed sale by a pre-IPO investor may signal a desire to take profits post-IPO, but the filing alone does not confirm the sale will occur.
SEPN drugs
SEPN drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 13 $42.60entry
- T+1 · 15h ago −2.18%α −0.27% · $41.67
- T+5 · in 3d Pending
- T+20 · in 27d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Samsara BioCapital, L.P., a significant shareholder in Septerna, filed a Form 144 notice of intent to sell 306,645 shares of common stock, with an approximate market value of $14.9 million. This represents a notable insider sale by a pre-IPO investor, though it is only an intent to sell and may not be executed.
Key Facts
- Samsara BioCapital, L.P. filed Form 144 on November 12, 2026
- Proposed sale of 306,645 shares of Septerna common stock
- Estimated aggregate market value of $14,890,681.20 based on a price of $48.55 per share
- Shares were acquired on October 25, 2024 in the IPO
- Samsara BioCapital is a venture capital firm and pre-IPO investor
- The filing is an advance notice of intent to sell, not a completed transaction
Financial Impact
Up to 306,645 shares sold, valued at approximately $14.9 million based on the filing price
Risk Factors
- Insider selling by a significant pre-IPO shareholder could pressure the stock if executed
- Form 144 is only an intent to sell; the actual sale may not happen or may be at different terms
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001628280-26-073519 |
| Document: 0001628280-26-073519-index.html | 0001628280-26-073519 |
| Document: 0001628280-26-073519.txt | 0001628280-26-073519 |
Track record
25 reports on SEPN
7 of 7 bullish or bearish reports moved the stock their way by T+5. Best: +55.96% at T+60 after the Apr 13, 2026 report. 8 of 8 went positive at some point.
Filters
- Nov 16, 2026today Insider Cluster Neutral 2/10 Entry price pending
- Nov 16, 2026today 144 Neutral 2/10 Entry price pending
- Nov 12, 20264d ago 144 Neutral 3/10 Viewing Entry $42.60 Now $41.67 −2.18% settles Nov 20
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $42.60 Now $41.67 −2.18% settles Nov 20
- Nov 12, 20264d ago 144 Neutral 3/10 Entry $41.86 Now $41.67 −0.45% settles Nov 19
- Nov 9, 20267d ago Press Release Bearish 5/10 Entry $52.34 Now $41.67 +20.39% settles Nov 17
- Nov 4, 202612d ago 8-K Neutral 3/10 Entry $47.88 to $48.56 Now $41.67 −12.97% ▲ +1.42% +2.33% vs SPY
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $47.88 to $48.56 Now $41.67 −12.97% ▲ +1.42% +2.33% vs SPY
- Sep 10, 20269w ago Press Release Neutral 2/10 Entry $38.51 to $38.69 Now $41.67 +8.21% ▲ +0.47% +0.69% vs SPY
- Sep 3, 202610w ago 3 Neutral 2/10 Entry $36.75 to $39.55 Now $41.67 +13.39% ▲ +7.62% +8.83% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers